In a report released today, Michael Petusky from Barrington maintained a Buy rating on Orthofix, with a price target of $17.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Michael Petusky has given his Buy rating due to a combination of factors, including Orthofix’s strong financial performance in the second quarter. The company’s revenue of $203.1 million surpassed both the firm’s and the consensus estimates, driven by robust sales in bone growth therapies and global orthopedics. Additionally, Orthofix’s adjusted earnings per share and EBITDA significantly exceeded expectations, reflecting effective expense management and operational efficiency.
Orthofix’s balance sheet remains solid with $68.7 million in cash and restricted cash, alongside a manageable debt level. The company also reaffirmed its financial guidance for 2025, projecting continued revenue growth and positive free cash flow. These positive financial indicators, combined with an increased price target of $17, support Petusky’s optimistic outlook and Buy rating for Orthofix’s stock.
In another report released yesterday, Roth MKM also maintained a Buy rating on the stock with a $22.00 price target.